Search
for
Sort by
Research 30 of 333
- Is knowledge about the genetic and epigenetic alterations in melanoma a basis for targeted therapy?
- Melanocytes: The new Black
- Diagnosis and Management of Melanoma of the Scalp: A Review of the Literature
- Diseases of the Canine Prostate Gland
- 696 MEK and BRAF inhibitors augment the production and accumulation of sebum in hamster sebocytes
- B-Raf and C-Raf Are Required for Melanocyte Stem Cell Self-Maintenance
- Genetics of thyroid lesions updated
- Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells
- Inflammatory and non-melanocytic tumoral pathology of the nail
- Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
- Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effects
- 554 Repurposing a clinical antimalarial for the therapeutic induction of lethal ER stress targeting BRAF-kinase inhibitor-resistant malignant melanoma
- Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
- A cross-sectional study of clinical, dermoscopic, histopathological, and molecular patterns of scalp melanoma in patients with or without androgenetic alopecia
- Cutaneous Drug Eruptions Associated with the Use of New Oncological Drugs
- A cross-sectional study of clinical, dermoscopic, histopathological, and molecular patterns of scalp melanoma in patients with or without androgenetic alopecia
- Exploiting the origins of Ras mediated squamous cell carcinoma to develop novel therapeutic interventions
- Progress in Dermatology and Venereology in 2023 as reflected in the Journal of the European Academy of Dermatology and Venereology
- Natural Compounds Targeting MAPK, PI3K/Akt, and JAK/STAT Signaling in Papillary Thyroid Cancer
- LB1031 Immune Cell-Mediated Amplification of Stem Cell Activation in Hairy Melanocytic Nevus via Osteopontin-CD44 Axis
- Can you diagnose hair loss (Non-scarring alopecia)
- Investigation of variants of the aromatase gene (CYP19A1) in female pattern hair loss
- The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: the Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma
- Lentiginous melanoma. A clinically malignant entity that histopathologically seems benign. Case study harbouring BRAF V 600R mutation
- B‐ RAF , naevi and melanoma: a complex relationship
- 129 Genetic transformation of keratoacanthoma-type cutaneous squamous cell carcinoma following intralesional chemotherapy
- Melanotic pigmentation in excisional scar of melanoma patient who received BRAF and MEK inhibitors
- Deciphering the cellular landscape and genetic underpinnings of fiber diameter determined by dermal papilla cells in fine-wool sheep
- Montagna Symposium 2017—Precision Dermatology: Next Generation Prevention, Diagnosis, and Treatment
- BRAF Inhibitor Dabrafenib in Patients with Metastatic <i>BRAF</i>-Mutant Thyroid Cancer